754,566 Shares in Chimerix, Inc. (NASDAQ:CMRX) Acquired by Peapod Lane Capital LLC

Peapod Lane Capital LLC purchased a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 754,566 shares of the biopharmaceutical company’s stock, valued at approximately $2,626,000. Chimerix makes up 2.6% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 11th biggest holding. Peapod Lane Capital LLC owned about 0.84% of Chimerix at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Stoneridge Investment Partners LLC increased its holdings in Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 8,134 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 496,823 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research report on Monday, December 30th.

Chimerix Price Performance

CMRX opened at $4.44 on Thursday. The company’s 50 day simple moving average is $3.38 and its two-hundred day simple moving average is $1.77. Chimerix, Inc. has a 1-year low of $0.75 and a 1-year high of $4.48.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.